Advertisement

Product › Details
Exovax platform
![]() |
Next higher product group | vaccine technology_o |
![]() |
Status | 2017-11-06 existent |
![]() |
Organisation | Nouscom AG |
Group | Nouscom (Group) | |
Record changed: 2023-07-10 |
Advertisement

More documents for vaccine technology_o
- [1] University of Bristol. (10/7/21). "Press Release: Collaborative COVID-19 Lockdown Effort Delivers Major Boost for Vaccine Innovation in Bristol"....
- [2] Osivax SAS. (7/8/20). "Press Release: Osivax Receives Over EUR 30m in Public Funding to Support Development of Universal Coronavirus & Influenza Vaccines". Lyon....
- [3] Merck & Co., Inc.. (5/26/20). "Press Release: Merck to Acquire Themis". Kenilworth, NJ....
- [4] Themis Bioscience GmbH. (8/22/19). "Press Release: Themis Bioscience Announces Exclusive License and Research Collaboration Agreement with MSD to Develop Vaccine Candidates". Vienna....
- [5] Boehringer Ingelheim. (7/15/19). "Press Release: Boehringer Ingelheim Acquires Amal Therapeutics, Significantly Enriching Its Cancer Immunology Portfolio with Novel Cancer Vaccines Platform". Ingelheim & Geneva....
To subscribe to our free, monthly newsletter for the European life sciences, please send an e-mail to [email protected] and simply fill the subject line with the word »LSE Newsletter«
Find more infos about advertising at [iito] web portals in our media flyer [iito] in a Nutshell [PDF file]
Please visit also our web portals for the European life sciences and the worldwide mass spectrometry industry at Life-Sciences-Europe.com (European life sciences) and Mass-Spec-Capital.com (worldwide mass spectrometry)
Please visit also our web portals for the life sciences in German-speaking Europe (DE, AT & CH) and the worldwide mass spectrometry industry at Life-Sciences-Germany.com (life sciences in German-speaking Europe) and Mass-Spec-Capital.com (worldwide mass spectrometry)
Advertisement

» top